XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Haematology - Multiple Myeloma

A LIST OF OUR EARLY PHASE Haematology (Multiple myeloma) TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALS

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

 

ProMMise

A Platform trial for Relapsed patients to evaluate Ongoing novel therapies in Multiple Myeloma In combination with Standard of care therapies

Local Project Reference:134457
Principal Investigator:Dr. Rakesh Popat
Drug Class/ Treatment:Benlantamab Mafodotin (Anti-BCMA IgG1 Antibody-Drug Conjugate)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

DTP3

Treating Multiple Myeloma and Diffuse Large B Cell Lymphoma by Targeting the NFκB Pathway with the First-in-Class GADD45β/MKK7 Inhibitor, DTP3

Local Project Reference:145878
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:

DTP3 (GADD45β/MKK7 Inhibitor)

Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

79635322MMY1001

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Local Project Reference:151562
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:

JNJ-79635322 - Trispecific Antibody

Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

CA057-003 (CC-92480)

An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma

Local Project Reference:147900
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:Mezigdomide (CC-92480) - Cereblon (CRBN) E3 Ligase Modulating Drug (CELMoD)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

TCD17710

First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell mat ration antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory lightchain amyloidosis (RRLCA)

Local Project Reference:1007232
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:

SAR445514 (NK-Cell Engager (NKCE) Targeting BCMA)

Patient Population:

Multiple Myeloma

Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

CAMMA - GO42552

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 1)

Local Project Reference:146840
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:

Cevostamab (GO425552) - Bi-specific T-Cell Engager

Arm B - Combnation with Pomalidomide + Dexamethasone

Patient Population:

Multiple Myeloma

Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

BGB-11417-105

A phase 1b/2 Dose-Escalation and Cohort-Expansion Study to determine the Safety and Efficacy of BGB11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

Local Project Reference: 
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:

BGB-11417 (BCL2 Inhibitor)

Monotherapy, In Combination with Dexamethasone and In Combination with Dexamethasone/Carfilzomib

Patient Population:

Multiple Myeloma

Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

M24-108

A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma

Local Project Reference: 
Principal Investigator:Dr Rakesh Popat
Drug Class/ Treatment:ABBV-383 (B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody)
Patient Population:Multiple Myeloma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)